Stayble resolves on a rights issue in order to ensure the completion of the ongoing phase 2b study
Stayble Therapeutics AB (“Stayble” or “the Company”) announces that the Board of Directors, with support of the authorization from the Annual General Meeting in 2019, has resolved on a new issue of shares in which the public is also given the opportunity to participate . The rights issue can provide the Company with a maximum of approximately SEK 41.5 million before issue costs. Prior to the rights issue, existing shareholders and external investors have entered subscription commitments totalling approximately SEK 19.8 million (corresponding to approximately 48 percent of the rights issue).